12 May 2023: Clinical Research
Outcomes of the Indonesian Chronic Disease Management Program (PROLANIS) in Patients with Hypertension During the COVID-19 Pandemic in Rural Areas: A Preliminary Evaluation Study
Sovia Salamah 12ACDEF* , Asiyah Nida Khafiyya 3DEF* , Ristra Ramadhani 4ABE , Mega Rizkya Arfiana 5BE , Ibrahim Syamsuri 6BE , Novia Nurul Faizah 5BE , David Nugraha 5EF , Bustanul Arifin 78DE* , Firas Farisi Alkaff 29ACE*DOI: 10.12659/MSM.939797
Med Sci Monit 2023; 29:e939797
Table 3 Six-month routine follow-up evaluation of study participants stratified based on their age.
| Evaluated parameters | Age <60 years oldN=39 | Age ≥60 years oldN=52 | ||||
|---|---|---|---|---|---|---|
| T0 | T1 | T2 | T0 | T1 | T2 | |
| BMI in Kg/m, median [IQR] | 23.8 [22.1–25.8] | 23.8 [22.2–26.4] | 23.9 [22.2–25.7]=0.071 | 23.0 [20–24.4] | 22.9 [20.3–24.2] | 22.1 [20.3–24]=0.625 |
| SBP in mmHg, median [IQR] | 130 [120–140] | 130 [120–144] | 130 [120–140] | 130 [120–140] | 140 [130–150] | 140 [130–157] |
| DBP in mmHg, median [IQR] | 80 [70–90] | 80 [73–90]=0.163 | 80 [70–90]=0.116 | 80 [80–90] | 85 [80–90] | 81 [79–90]=0.392 |
| TC in mg/dl, mean±SD | 212±39 | 216±40=0.442 | 214±44=0.724 | 204±44 | 218±41 | 199±39=0.425 |
| LDL in mg/dl, mean±SD | 138±37 | 134±37=0.504 | 133±43=0.575 | 125±42 | 134±34 | 120±34=0.391 |
| HDL in mg/dl, median [IQR] | 55 [49–62] | 58 [50–68]=0.634 | 45 [41–51] | 54 [47–65] | 56 [48–66]=0.923 | 44 [–]37 |
| TG in mg/dl, median [IQR] | 133 [105–194] | 129 [107–188]=0.238 | 139 [94–183]=0.655 | 152 [103–209] | 151 [98–213]=0.272 | 146 [100–200]=0.158 |
| eGFR in ml/min/1.73 m, mean±SD | 87.9±20 | 84.8±20.6=0.267 | 82.2±21.6=0.116 | 75.5±16.2 | 69.2±19.9 | 69.6±19.1 |
| BMI – body mass index; DBP – diastolic blood pressure; eGFR – estimated glomerular filtration rate based on CKD-EPI equation; HDL – high-density lipid; LDL – low-density lipid; TC – total cholesterol; TG – triglyceride; T0 – 6-month routine evaluation conducted in December 2019; T1 – 6-month routine evaluation conducted in June 2020; T2 – 6-month routine evaluation conducted in December 2020. Paired t-test was used for normally distributed data and Wilcoxon-signed rank test was used for skewed data. | ||||||